Product Images Clopidogrel Bisulfate

This is a description for Clopidogrel, a medication used to prevent blood clots. Each tablet contains 3915 mg of clopidogrel bisulfate USP equivalent to 300 mg of clopidogrel base. The usual dosage information is available on the package insert. This medication should be stored at 20°-25°C (68°-77°F) in a controlled room temperature. The pack consisting of six tablets is not child-resistant, and it is for institutional use only. The blister card packaging each contains 6 tablets. The medication is available in a pack of 30 (5 x 6 unit-dose) Tablets.*

This is an information leaflet for clopidogrel bisulfate tablets, with each tablet containing 391.5mg of the bisulfate and 300mg of clopidogrel base. The typical dosage instructions are provided in the package insert. The medication is to be stored at a controlled room temperature of 20-25°C. The unit-dose packaging is not child-resistant, and the tablets are for institutional use only. The label also shows the NDC number and the manufacturer's name, Dr. Reddy's Laboratories. The text on the label also includes the name of the medicine, the lot number, and some reference codes.*

This table shows the effect of administering PPI in combination with certain medications on the active metabolite AUC. The medications included are dexlansoprazole, lansoprazole, pantoprazole, and omeprazole. The values represent the mean and 90% confidence interval. It is unclear what the units of measurement are.*

This is a chart displaying the cumulative event rate in percentage for a drug called Clopidogrel with aspirin, compared to another drug called Placebo with aspirin. The data was collected over a duration of several months. Other standard therapies were also used during the study.*

This appears to be the result of a study comparing the efficacy of a placebo and clopidogrel in reducing the proportion of deaths in a certain period of time since randomization. The study found that participants taking clopidogrel had a 7% proportional risk reduction in mortality compared to those taking a placebo (with a p-value of 0.03). The numbers indicate that 1845 out of the total participants taking the placebo died (8.1%) while only 1726 taking clopidogrel died (7.5%). The timeframe of the study was up to 28 days post-randomization.*

This is a clinical study evaluating the effect of Clopidogrel on patients with a risk of death, reinfarction, or stroke before the first discharge. The study involved a group of 2310 patients who were administered a placebo and 2121 patients who were administered Clopidogrel. The results showed a proportional risk reduction of 9% in patients administered with Clopidogrel compared to those who took the placebo. This reduction was significant with a p-value of 0.002. The study was conducted within a period of up to 28 days.*